Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.2174/1573403X15666181212125024 http://scihub22266oqcxt.onion/10.2174/1573403X15666181212125024 30543176!6520577!30543176     free     free     free Deprecated: Implicit conversion from float 233.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 233.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 233.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       Curr+Cardiol+Rev 2019 ; 15 (2): 102-113 Nephropedia Template TP {{tp|p=30543176|t=2019. Shock - Classification and Pathophysiological Principles of Therapeutics |pdf=|usr=}}{{30543176}} gab.com Text Shock - Classification and Pathophysiological Principles of Therapeutics JO: Curr Cardiol Rev http://www.kidney.de/pget.php?&tw=1&pmid=30543176 #FOAvip The management of patients with shock is extremely challenging because of the myriad of possible clinical presentations in cardiogenic shock, septic shock and hypovolemic shock and the limitations of contemporary therapeutic options. The treatment of shock includes the administration of endogenous catecholamines (epinephrine, norepinephrine, and dopamine) as well as various vasopressor agents that have shown efficacy in the treatment of the various types of shock. In addition to the endogenous catecholamines, dobutamine, isoproterenol, phenylephrine, and milrinone have served as the mainstays of shock therapy for several decades. Recently, experimental studies have suggested that newer agents such as vasopressin, selepressin, calcium-sensitizing agents like levosimendan, cardiac-specific myosin activators like omecamtiv mecarbil (OM), istaroxime, and natriuretic peptides like nesiritide can enhance shock therapy, especially when shock presents a more complex clinical picture than normal. However, their ability to improve clinical outcomes remains to be proven. It is the purpose of this review to describe the mechanism of action, dosage requirements, advantages and disadvantages, and specific indications and contraindications for the use of each of these catecholamines and vasopressors, as well as to elucidate the most important clinical trials that serve as the basis of contemporary shock therapy. Twit Text FOAVip Shock - Classification and Pathophysiological Principles of Therapeutics ????Curr Cardiol Rev http://www.kidney.de/pget.php?&tw=1&pmid=30543176 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=30543176 #FOAvip English Wikipedia <ref>{{Cite pmid|30543176}}</ref> Shock - Classification and Pathophysiological Principles of Therapeutics #MMPMID30543176 Kislitsina ON; Rich JD; Wilcox JE; Pham DT; Churyla A; Vorovich EB; Ghafourian K; Yancy CW Curr Cardiol Rev 2019[]; 15 (2): 102-113 PMID30543176show ga The management of patients with shock is extremely challenging because of the myriad of possible clinical presentations in cardiogenic shock, septic shock and hypovolemic shock and the limitations of contemporary therapeutic options. The treatment of shock includes the administration of endogenous catecholamines (epinephrine, norepinephrine, and dopamine) as well as various vasopressor agents that have shown efficacy in the treatment of the various types of shock. In addition to the endogenous catecholamines, dobutamine, isoproterenol, phenylephrine, and milrinone have served as the mainstays of shock therapy for several decades. Recently, experimental studies have suggested that newer agents such as vasopressin, selepressin, calcium-sensitizing agents like levosimendan, cardiac-specific myosin activators like omecamtiv mecarbil (OM), istaroxime, and natriuretic peptides like nesiritide can enhance shock therapy, especially when shock presents a more complex clinical picture than normal. However, their ability to improve clinical outcomes remains to be proven. It is the purpose of this review to describe the mechanism of action, dosage requirements, advantages and disadvantages, and specific indications and contraindications for the use of each of these catecholamines and vasopressors, as well as to elucidate the most important clinical trials that serve as the basis of contemporary shock therapy. |Humans[MESH] |Shock, Cardiogenic/*physiopathology[MESH] |Shock, Septic/*physiopathology[MESH] |Shock/*classification/*physiopathology[MESH]Shock - Classification and Pathophysiological Principles of Therapeuti(epmc).pdf DeepDyve Pubget Overpricing